Good — MRSH corresponds to MMC (Marsh & McLennan) in the documents database. Let me gather the latest earnings call transcript (2026Q1), the most recent 10-Q, and other relevant materials.# Marsh & McLennan Companies (MMC/MRSH) — Q2 2026 Earnings Preview
Report Date: Tuesday, July 21, 2026 (before market open) | Earnings Call: 8:30 a.m. ET
Marsh & McLennan — the parent of Marsh, Guy Carpenter, Mercer, and Oliver Wyman/Marsh Management Consulting — heads into its Q2 print as the insurance broker group grapples with a decelerating property-casualty pricing cycle. The stock has been volatile in 2026, falling from roughly $190 in early February to a 2026 low near $157 in early June before recovering to roughly $182 heading into the print — essentially flat year-to-date but well off its highs, reflecting investor anxiety about the organic growth outlook as commercial insurance and reinsurance rates keep falling.
Sell-side sentiment is mixed: Morgan Stanley trimmed its price target to $175 from $180 in early July, while UBS has reiterated a Buy rating, and the broader consensus rating sits around "Hold" with an average street price target in the $200-$210 area — implying analysts see upside from current levels even as near-term estimates have drifted lower (Zacks noted the Q2 EPS estimate has seen three downward revisions and no upward revisions over the past 60 days).
Estimates vary slightly by source, but the general range going into the print is:
| Metric | Consensus (range across sources) | Q2 2025 Actual |
|---|---|---|
| Adjusted EPS | ~$2.88–$2.96 | $2.72 |
| Revenue | ~$7.27B–$7.44B | $6.97B |
| Underlying (organic) revenue growth | ~3.6% (RIS ~3.1%) | 4% |
| Adjusted operating margin | ~29.3% | 29.5% |
For full-year 2026, the Street models adjusted EPS of roughly $10.37–$10.38, up ~6.5% from 2025's $9.75, with 2027 EPS expected to accelerate further to ~$11.25 (+8.4%).
The Q1 2026 report (revenue +8% reported/+4% underlying, adjusted EPS +8% to $3.29, margin flat at 31.8%) set the tone for the year, and several threads carry directly into Q2:
a) Decelerating pricing is the central swing factor. Management noted that in Q1, primary commercial insurance rates fell 5% globally (driven by a 9% drop in property), while reinsurance conditions remained soft — U.S. property-cat reinsurance rates were down 15-20% at the April 1 renewal, "a slight acceleration from the January 1 renewal season." Guy Carpenter grew just 2% underlying in Q1 against a tough prior-year comp, and CEO John Doyle flagged that 2026 is "not likely to be Guy Carpenter's best growth year." Investors should watch whether Marsh Risk's sequential improvement (accelerating to 4% underlying in Q1) continued, and whether Guy Carpenter stabilized or slipped further given continued cat-bond issuance and ample reinsurance capacity.
b) Consulting (Mercer/Oliver Wyman) has been the relative bright spot. Consulting grew 5% underlying in Q1 (Mercer +5%, driven by Health +6% and Wealth +5% on AUM growth to $727B; Oliver Wyman/Marsh Management Consulting +6%), partially offset by continued softness in Mercer's Career project work. This segment's momentum, along with the pending AltamarCAM acquisition (a ~€20 billion AUM private-markets specialist being acquired by Mercer, expected to close in H2 2026), is central to the diversification story management is emphasizing as a hedge against P&C cyclicality.
c) Fiduciary interest income and rates remain a headwind. Management guided Q2 fiduciary interest income to approximately $80 million, continuing the year-over-year decline (Q1 was down $18 million YoY) as interest rates fall — a modest but persistent drag on RIS profitability that investors will want to see quantified again this quarter.
d) Margin expansion and the "19th consecutive year" narrative. Management reiterated its commitment to margin expansion for a 19th straight year in 2026, explicitly guiding that "more margin expansion" would come in the second half than the first half — meaning Q2 margin comparisons could still look modest even if the full-year trajectory remains intact. The Thrive efficiency program (targeting $400 million of total savings against ~$500 million of charges, with AI-driven automation in the new Business & Client Services unit as a key lever) is the mechanism management points to for sustaining margins even as top-line growth slows.
e) The Greensill litigation overhang. Q1 included a $425 million charge tied to Australian Greensill Capital-related litigation (Marsh served as Greensill's insurance broker starting in 2014), following court-sponsored mediation; claims in the broader case reportedly total around $5 billion plus interest and costs. Since this remains active litigation, investors should watch for any incremental disclosure, reserve changes, or commentary in the Q2 10-Q and call, even though management has said it can't comment extensively while proceedings are ongoing.
f) Capital deployment / M&A vs. buybacks. MMC repurchased $750 million of stock in Q1 and reiterated plans to deploy ~$5 billion of capital in 2026 across dividends, M&A, and buybacks. With the stock having pulled back meaningfully from its 2026 highs, watch for commentary on whether buyback pace stayed elevated in Q2 or whether M&A (beyond AltamarCAM) absorbed more capital — CFO Mark McGivney has said buyback levels will flex depending on how the M&A pipeline develops.
g) AI positioning. Management has framed AI as a three-pillar opportunity (growth via new AI-enabled products like Aida, Sentrisk, GC QuoteBox, Mercer Fiber; productivity; and efficiency via the BCS unit), and used the Q1 call to push back on investor concerns about AI-driven fee/margin disintermediation. Expect continued emphasis on this theme, as well as further specifics on tools like the "Marsh Risk Cortex" analytics platform slated for rollout.
Beyond company-specific drivers, results will be read against a mixed macro tape: ongoing Middle East geopolitical tension (which management said has had limited direct impact on the insurance book, mainly affecting marine/war-risk pricing), still-elevated liability and medical cost inflation pressuring the "cost of risk" narrative that underpins long-term demand for Marsh's advisory services, and a broader insurance-broker peer group where Aon (Q1 2026: 5% organic growth, adjusted EPS +14%) and WTW (Q1 2026: 3% organic growth) have shown a similar pattern of solid execution amid a softening rate environment.
The setup into Q2 is one of "steady execution, decelerating tailwinds." Consensus implies roughly 6-9% adjusted EPS growth and mid-single-digit underlying revenue growth — consistent with management's full-year framework of underlying growth "similar to 2025" plus continued (back-half-weighted) margin expansion. The key swing factors to watch on the print and call are: (1) whether Marsh Risk's organic growth held up or decelerated further as commercial rates keep falling; (2) whether Guy Carpenter stabilized after a soft Q1; (3) any incremental Greensill disclosure; (4) capital deployment pace (buybacks vs. M&A, including AltamarCAM timing); and (5) fresh detail on margin cadence and Thrive/AI savings that underpin the "19 consecutive years of margin expansion" claim. Given the stock's pullback from 2026 highs and mixed analyst price-target action, the market appears to be pricing in some organic growth deceleration already — making the magnitude of any beat/miss on underlying growth and margin trajectory the most market-moving variables tomorrow.